Impact of Different Contraceptives on the Immune System of HIV Infected Women in Zambia (MSRC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.

In this study, 66 HIV-infected women who desire contraception will be randomly assigned to use either an IUD or Depo Provera, and will be followed for six months. The study is intended to help investigators understand potential mechanisms by which hormonal contraception may hasten HIV disease progression.

Condition or disease

Intervention/treatment

Phase

HIVContraceptionHIV Infections

Drug: Depo ProveraDevice: Copper T Intrauterine contraception device

Phase 2

Detailed Description:

In this randomized controlled trial, 66 HIV-infected women who desire contraception will be assigned to one of two treatment groups: IUD or Depo Provera. The study builds on findings from a previous study which examined the safety and acceptability of hormonal contraception and IUD among HIV-infected women. Secondary analyses from the previous study indicated that women who were assigned to the hormonal arm appeared to have faster disease progression based on death and decline in CD4+ count as compared to women assigned to the IUD arm. With the current study, investigators seek to understand potential mechanisms for the effect of hormonal contraception on hastening HIV disease progression. Enrolled women will be asked to use the assigned contraception method for a period of six months, and various indicators of disease progression will be collected at four follow-up visits after randomization.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:

16 Years and older (Child, Adult, Senior)

Sexes Eligible for Study:

Female

Accepts Healthy Volunteers:

No

Criteria

Inclusion Criteria:

Confirmed HIV status by local rapid test algorithm

Willingness to be randomized to a contraceptive method and continue that method for at least 6 months.

Intention to stay in the study area for at least 6 months

Exclusion Criteria:

Currently pregnant or pregnant within the prior 6 months

Currently breastfeeding

Documented liver disease

History of coagulation disorder

Active tuberculosis

Anemia, defined as Hgb <8gm/dL

Age < 16 years (the age of consent in Zambia);

Eligible for antiretroviral therapy based on Zambian National Guidelines (CD4+ < 200, or WHO stage IV, or CD4+< 350 and WHO stage III)

Currently using an IUD or hormonal method of contraception, or have used a hormonal contraceptive in the past 6 months